Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allopurinol + thiopurine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy using allopurinol with reduced-dose thiopurines (azathioprine or 6-mercaptopurine) for inflammatory bowel disease treatment. This approach optimizes thiopurine metabolism by increasing therapeutic 6-thioguanine (6-TGN) levels while decreasing potentially toxic 6-methyl-mercaptopurine (6-MMP) levels, resulting in improved clinical outcomes and reduced side effects.
- Other names
- allopurinol-thiopurine combination therapythiopurine-allopurinol co-therapylow-dose thiopurine with allopurinolLDAA
02
Targets
TPMT (Thiopurine S-methyltransferase)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on allopurinol + thiopurine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allopurinol + thiopurine.